JP2019526540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526540A5 JP2019526540A5 JP2019504902A JP2019504902A JP2019526540A5 JP 2019526540 A5 JP2019526540 A5 JP 2019526540A5 JP 2019504902 A JP2019504902 A JP 2019504902A JP 2019504902 A JP2019504902 A JP 2019504902A JP 2019526540 A5 JP2019526540 A5 JP 2019526540A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- seq
- isolated antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022100315A JP7442575B2 (ja) | 2016-07-29 | 2022-06-22 | Ｆｃｒｎ抗体及びその使用方法 |
| JP2024023875A JP2024059765A (ja) | 2016-07-29 | 2024-02-20 | Ｆｃｒｎ抗体及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368803P | 2016-07-29 | 2016-07-29 | |
| US201662368770P | 2016-07-29 | 2016-07-29 | |
| US62/368,770 | 2016-07-29 | ||
| US62/368,803 | 2016-07-29 | ||
| PCT/US2017/044765 WO2018023136A1 (en) | 2016-07-29 | 2017-07-31 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100315A Division JP7442575B2 (ja) | 2016-07-29 | 2022-06-22 | Ｆｃｒｎ抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526540A JP2019526540A (ja) | 2019-09-19 |
| JP2019526540A5 true JP2019526540A5 (cg-RX-API-DMAC10.html) | 2020-09-03 |
| JP7094941B2 JP7094941B2 (ja) | 2022-07-04 |
Family
ID=61016731
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504902A Active JP7094941B2 (ja) | 2016-07-29 | 2017-07-31 | Ｆｃｒｎ抗体及びその使用方法 |
| JP2022100315A Active JP7442575B2 (ja) | 2016-07-29 | 2022-06-22 | Ｆｃｒｎ抗体及びその使用方法 |
| JP2024023875A Pending JP2024059765A (ja) | 2016-07-29 | 2024-02-20 | Ｆｃｒｎ抗体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100315A Active JP7442575B2 (ja) | 2016-07-29 | 2022-06-22 | Ｆｃｒｎ抗体及びその使用方法 |
| JP2024023875A Pending JP2024059765A (ja) | 2016-07-29 | 2024-02-20 | Ｆｃｒｎ抗体及びその使用方法 |
Country Status (22)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| BR112019001806A2 (pt) * | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| BR112019023687A2 (pt) | 2017-05-11 | 2020-06-02 | National University Of Singapore | Prevenção direcionada de transmissão de infecção vertical de mãe para feto |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) * | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| US12054558B2 (en) | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| IL280280B2 (en) * | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| EP3969125A4 (en) * | 2019-05-17 | 2023-01-11 | Alexion Pharmaceuticals, Inc. | USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| EP4061486A1 (en) * | 2019-11-19 | 2022-09-28 | Immunovant Sciences GmbH | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CN116234827B (zh) * | 2021-09-03 | 2026-07-14 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| WO2024147074A1 (en) * | 2023-01-06 | 2024-07-11 | argenx BV | Methods for treating pots using fcrn antagonists |
| USD1123829S1 (en) * | 2023-10-10 | 2026-04-28 | Shenzhen WETON Technology Co., Ltd. | Rechargeable card holder |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1345751A (en) | 1918-09-23 | 1920-07-06 | Dewrance John | Multiple-way stop-valve |
| AU3928593A (en) | 1992-04-01 | 1993-11-08 | Merck & Co., Inc. | Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| EP2666478A3 (en) | 2006-04-10 | 2014-10-22 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of psoriasis |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| US8273351B2 (en) | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| PY1147875A (es) | 2010-11-08 | 2015-08-03 | Novartis Ag | Polipéptidos de enlace de los receptores de quimiocina |
| CN103026413B (zh) | 2011-02-15 | 2016-04-20 | 松下电器产业株式会社 | 转台 |
| US9067997B2 (en) | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| BR112013030352B1 (pt) * | 2011-06-02 | 2020-05-19 | Dyax Corp. | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
| US9959576B2 (en) | 2011-12-07 | 2018-05-01 | Visa International Service Association | Multi-purpose device having multiple certificates including member certificate |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| JP5986637B2 (ja) | 2012-09-26 | 2016-09-06 | テルモ株式会社 | 薬液投与装置 |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) * | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| US20150291689A1 (en) | 2014-03-09 | 2015-10-15 | Abbvie, Inc. | Compositions and Methods for Treating Rheumatoid Arthritis |
| EP4241852A3 (en) * | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| PL3590962T3 (pl) | 2014-10-23 | 2022-01-31 | Singh Molecular Medicine, Llc | Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym |
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| CA3022547A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| KR20190015704A (ko) | 2016-04-25 | 2019-02-14 | 신티뮨, 인크. | 인간화된 친화성 성숙 항-fcrn 항체 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| WO2018063963A1 (en) | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| WO2018142618A1 (ja) | 2017-02-06 | 2018-08-09 | 三菱電機株式会社 | スケジューラ装置およびスケジューリング方法 |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| MX2020003619A (es) | 2017-10-04 | 2020-10-28 | Alexion Pharma Inc | Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa. |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EP3762027A4 (en) | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| WO2019194277A1 (ja) | 2018-04-05 | 2019-10-10 | 株式会社Ｓｏｋｅｎ | 飛行装置および飛行装置誘導システム |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| KR20260109977A (ko) | 2018-08-29 | 2026-07-13 | 리제너론 파아마슈티컬스, 인크. | 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물 |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| CN113423426B (zh) | 2018-11-06 | 2025-02-18 | 依牧诺万科学有限公司 | 使用抗FcRn抗体治疗格雷夫斯眼病的方法 |
| CA3148826A1 (en) | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CA3183153A1 (en) | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| CA3200972A1 (en) | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| MX2023012032A (es) | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| WO2022240875A1 (en) | 2021-05-13 | 2022-11-17 | Scipher Medicine Corporation | Assessing responsiveness to therapy |
-
2017
- 2017-07-31 BR BR112019001806-9A patent/BR112019001806A2/pt active Search and Examination
- 2017-07-31 KR KR1020237006882A patent/KR102717601B1/ko active Active
- 2017-07-31 FI FIEP17835436.1T patent/FI3491025T3/fi active
- 2017-07-31 CA CA3032415A patent/CA3032415A1/en active Pending
- 2017-07-31 DK DK17835436.1T patent/DK3491025T3/da active
- 2017-07-31 JP JP2019504902A patent/JP7094941B2/ja active Active
- 2017-07-31 IL IL264528A patent/IL264528B2/en unknown
- 2017-07-31 RS RS20240046A patent/RS65070B1/sr unknown
- 2017-07-31 HU HUE17835436A patent/HUE065780T2/hu unknown
- 2017-07-31 HR HRP20240048TT patent/HRP20240048T1/hr unknown
- 2017-07-31 ES ES17835436T patent/ES2968439T3/es active Active
- 2017-07-31 SG SG11201900813RA patent/SG11201900813RA/en unknown
- 2017-07-31 SM SM20240004T patent/SMT202400004T1/it unknown
- 2017-07-31 LT LTEPPCT/US2017/044765T patent/LT3491025T/lt unknown
- 2017-07-31 SI SI201731447T patent/SI3491025T1/sl unknown
- 2017-07-31 KR KR1020247033727A patent/KR20240151878A/ko active Pending
- 2017-07-31 EP EP17835436.1A patent/EP3491025B1/en active Active
- 2017-07-31 IL IL320058A patent/IL320058A/en unknown
- 2017-07-31 PT PT178354361T patent/PT3491025T/pt unknown
- 2017-07-31 CN CN201780060620.6A patent/CN109790221B/zh active Active
- 2017-07-31 CN CN202311567291.8A patent/CN117679506A/zh active Pending
- 2017-07-31 US US16/321,801 patent/US11345751B2/en active Active
- 2017-07-31 IL IL302288A patent/IL302288B2/en unknown
- 2017-07-31 EP EP23195791.1A patent/EP4282487A3/en active Pending
- 2017-07-31 PL PL17835436.1T patent/PL3491025T3/pl unknown
- 2017-07-31 AU AU2017301915A patent/AU2017301915B2/en active Active
- 2017-07-31 KR KR1020197006049A patent/KR102505995B1/ko active Active
- 2017-07-31 WO PCT/US2017/044765 patent/WO2018023136A1/en not_active Ceased
-
2022
- 2022-04-28 US US17/661,070 patent/US12655209B2/en active Active
- 2022-06-22 JP JP2022100315A patent/JP7442575B2/ja active Active
-
2024
- 2024-02-20 JP JP2024023875A patent/JP2024059765A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016042A5 (cg-RX-API-DMAC10.html) | ||
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| JP2021506786A5 (cg-RX-API-DMAC10.html) | ||
| CN114630678A (zh) | FcRn抗体及其使用方法 | |
| JP2022528927A5 (cg-RX-API-DMAC10.html) | ||
| US20220144946A1 (en) | Fcrn antibodies and methods of use thereof | |
| JP2022542805A (ja) | メタロチオネイン抗体およびそれらの使用 | |
| CA2958030A1 (en) | Anti-hepatitis c antibodies and antigen binding fragments thereof | |
| HK40072884A (en) | Fcrn antibodies and methods of use thereof | |
| EA050428B1 (ru) | АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA051865B1 (ru) | Антитела к fcrn и способы их применения | |
| CN116782939A (zh) | FcRn抗体及其使用方法 |